Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca

Showing results (141-150 of 94,264) with videos related to

Pageof 9,427
Sort By:
Expert Opinion on Therapeutic Patents|July 20, 2012
Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluationLuca Costantino
Brain, Behavior, & Immunity - Health|September 13, 2021
Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expressionLuca Sforzini
The International Journal of Psycho-Analysis|May 4, 2021
Towards and beyond the Pillars of Hercules: Integration and transformation of destructiveness in child psychosis (the case of Amine)Luca Quagelli
Seminars in Nuclear Medicine|September 27, 2025
Glypican-3: Novel Theranostic Agent for Hepatocellular CarcinomaLuca Filippi
Physical Review Letters|December 19, 2025
Breaking Boundaries: Extending the Orbit-Averaged Fokker-Planck Equation Inside the Loss ConeLuca Broggi
F1000Research|February 7, 2025
CINNAMON-GUI: Revolutionizing Pap Smear Analysis with CNN-Based Digital Pathology Image ClassificationLuca Zammataro
Entropy (Basel, Switzerland)|November 27, 2024
Entropy-Based Volatility Analysis of Financial Log-Returns Using Gaussian Mixture ModelsLuca Scrucca
Journal of Clinical Medicine|August 10, 2024
Advancing Personalized Interventions: A Paradigm Shift in Psychological and Health-Related Treatment StrategiesLuca Cerniglia
Molecules (Basel, Switzerland)|June 19, 2024
State of the Art in the Development of Human Serum Carnosinase InhibitorsLuca Regazzoni
Annals of Internal Medicine|April 1, 2024
In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse eventsLuca Bertolaccini
Pageof 9,427

Showing results (141-150 of 94,264) with videos related to

Sort By:
Pageof 9,427
Expert Opinion on Therapeutic Patents|July 20, 2012
Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors (WO2012035124): a patent evaluationLuca Costantino
Brain, Behavior, & Immunity - Health|September 13, 2021
Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expressionLuca Sforzini
The International Journal of Psycho-Analysis|May 4, 2021
Towards and beyond the Pillars of Hercules: Integration and transformation of destructiveness in child psychosis (the case of Amine)Luca Quagelli
Seminars in Nuclear Medicine|September 27, 2025
Glypican-3: Novel Theranostic Agent for Hepatocellular CarcinomaLuca Filippi
Physical Review Letters|December 19, 2025
Breaking Boundaries: Extending the Orbit-Averaged Fokker-Planck Equation Inside the Loss ConeLuca Broggi
F1000Research|February 7, 2025
CINNAMON-GUI: Revolutionizing Pap Smear Analysis with CNN-Based Digital Pathology Image ClassificationLuca Zammataro
Entropy (Basel, Switzerland)|November 27, 2024
Entropy-Based Volatility Analysis of Financial Log-Returns Using Gaussian Mixture ModelsLuca Scrucca
Journal of Clinical Medicine|August 10, 2024
Advancing Personalized Interventions: A Paradigm Shift in Psychological and Health-Related Treatment StrategiesLuca Cerniglia
Molecules (Basel, Switzerland)|June 19, 2024
State of the Art in the Development of Human Serum Carnosinase InhibitorsLuca Regazzoni
Annals of Internal Medicine|April 1, 2024
In solid tumors, neoadjuvant or adjuvant immune checkpoint blockade increases treatment-related grade 3 or 4 adverse eventsLuca Bertolaccini
Pageof 9,427